XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
Three Months Ended
June 30,		Six Months Ended
June 30,
Net sales2020201920202019
MedSurg$576  $818  $1,350  $1,584  
Rhythm and Neuro525  786  1,228  1,543  
Cardiovascular834  1,026  1,860  1,998  
Total net sales of reportable segments1,935  2,631  4,437  5,124  
All other (Specialty Pharmaceuticals)68  n/a109  n/a
Consolidated net sales$2,003  $2,631  $4,546  $5,124  
Three Months Ended
June 30,		Six Months Ended
June 30,
Income (loss) before income taxes2020201920202019
MedSurg$173  $295  $432  $551  
Rhythm and Neuro32  167  131  322  
Cardiovascular186  301  385  577  
Total operating income of reportable segments391  763  947  1,449  
All other (Specialty Pharmaceuticals)49  n/a75  n/a
Unallocated amounts:
Corporate expenses, including hedging activities(189) (91) (222) (140) 
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits(125) (127) (327) (64) 
Amortization expense(197) (161) (398) (321) 
Operating income (loss)(71) 384  75  925  
Other expense, net(110) (239) (234) (323) 
Income (loss) before income taxes$(181) $145  $(159) $602  
Operating income of reportable segments as a percentage of net sales of reportable segmentsThree Months Ended
June 30,		Six Months Ended
June 30,
2020201920202019
MedSurg30.1 %36.1 %32.0 %34.8 %
Rhythm and Neuro6.1 %21.2 %10.7 %20.9 %
Cardiovascular22.3 %29.3 %20.7 %28.9 %